LA JOLLA, Calif., July 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation
(OTC Bulletin Board: IMYN) announced today that the distribution of SF-1019 in
the State of Utah is anticipated to begin shortly through Renewed Hope Clinic
in Beaver, Utah.
Immunosyn is negotiating an exclusive license agreement for the
administration and distribution of SF-1019 in the State of Utah with Utah
Biopharmaceutical Laboratories, LLC.
Immunosyn has been advised by Argyll Biotechnologies, LLC, the licensor of
SF-1019, Immunosyn's strategic partner and its largest shareholder, that
Argyll Biotech is negotiating a three-party agreement with its current
domestic third party manufacturer and Utah Biopharmaceutical Laboratories for
Utah Biopharmaceuticals Laboratories to be a third party manufacturer of
SF-1019 in the State of Utah. Argyll Biotech has worked for several years on
developing the manufacturing processes, protocols, safety procedures and
guidelines for SF-1019. Immunosyn, together with Argyll Biotech and Utah
Biopharmaceutical Laboratories, is working to finalize Distribution Management
and Information Component Systems that will be implemented to define protocols
to assure patient safety and regulatory compliance in Utah prior to treatment
commencing.
The combination of the proposed license and manufacturing agreements will
allow for SF-1019 to be administered in the State of Utah exclusively by Utah
Biopharmaceutical Laboratories through Renewed Hope Clinic which is located in
Beaver, Utah.
"I am excited to have the ability to treat patients with this therapeutic
modality, which is not yet available elsewhere in the U.S. My review of the
scientific background, preclinical testing, initial safety evaluations and
studies performed under compassionate waivers, coupled with the therapeutic
benefits I have witnessed, give me confidence in the benefit my patients will
receive from SF-1019 treatment," said Mitchell J. Melling, MD, Manager of Utah
Biopharmaceutical Laboratories, LLC.
Stephen D. Ferrone, President and CEO of Immunosyn, stated, "Utah
Biopharmaceutical Laboratories sought the ability to distribute SF-1019 in the
State of Utah as a result of the compelling desire of patients who are seeking
this treatment after their having failed conventional, FDA approved therapy.
This patient demand stemmed from the perceived benefit of treatment in
patients who participated in early preclinical studies and who desire ongoing
access to SF-1019 to alleviate their symptoms."
Ferrone added, "Argyll Biotech advises us that they plan to continue the
process to obtain full regulatory approvals for the marketing of SF-1019 in
both Europe and the U.S."
"This is an exciting early-stage development as this puts revenue
producing capabilities within short-term range for the company," stated
Douglas A. McClain, Jr., Chairman of the Board and CFO of Immunosyn.
About Utah Biopharmaceutical Laboratories, LLC
Utah Biopharmaceutical Laboratories was organized for the purpose of
manufacturing SF-1019 for administering and distributing by United
Biopharmaceutical Laboratories through the Renewed Hope Clinic under the
direction of Mitchell J. Melling, MD in the State of Utah.
About Renewed Hope Clinic
Located in Beaver, Utah at 95 North 400 East, Renewed Hope Clinic is
managed by Mitchell Melling, MD who is Board Certified in Family Practice in
the State of Utah. Renewed Hope Clinic is a family practice center,
emphasizing treatment of autoimmune and infectious diseases.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation
(OTC Bulletin Board: IMYN) plans to market and distribute life enhancing
therapeutics. Currently, the company has exclusive worldwide rights from its
largest shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive research into
Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has
initiated the process for regulatory approval of SF-1019 in several countries
and preparations for clinical trials are underway in both the U.S. and Europe.
Research suggests that SF-1019 has the potential to affect a number of
clinical conditions including complications from Diabetic Mellitus such as
Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such
as Multiple Sclerosis (MS) and neurological disorders such as Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic
Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and
SF-1019 go to http://www.immunosyn.com).
The above news release contains forward-looking statements. These
statements are based on assumptions that management believes are reasonable
based on currently available information, and include statements regarding the
intent, belief or current expectations of the Company and its management.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance, and are subject to a wide range of
business risks, external factors and uncertainties. Actual results may differ
materially from those indicated by such forward-looking statements. For
additional information, please consult the Company's most recent public
filings and Annual Report on Form 10-K for its most recent fiscal year. The
Company assumes no obligation to update the information contained in this
press release, whether as a result of new information, future events or
otherwise.
SOURCE Immunosyn Corporation